Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 17332347)


High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.

Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE.

Cancer Res. 2007 Mar 1;67(5):2169-77.


Defects in the fanconi anemia pathway and chromatid cohesion in head-and-neck cancer.

Stoepker C, Ameziane N, van der Lelij P, Kooi IE, Oostra AB, Rooimans MA, van Mil SE, Brink A, Dietrich R, Balk JA, Ylstra B, Joenje H, Feller SM, Brakenhoff RH.

Cancer Res. 2015 Jun 29. pii: canres.0528.2015. [Epub ahead of print]


Mutated Fanconi anemia pathway in non-Fanconi anemia cancers.

Shen Y, Lee YH, Panneerselvam J, Zhang J, Loo LW, Fei P.

Oncotarget. 2015 May 9. [Epub ahead of print]


Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer.

Senkowski W, Zhang X, Olofsson MH, Isacson R, Höglund U, Gustafsson M, Nygren P, Linder S, Larsson R, Fryknäs M.

Mol Cancer Ther. 2015 Jun;14(6):1504-16. doi: 10.1158/1535-7163.MCT-14-0792. Epub 2015 Apr 24.


Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents.

Wang GZ, Liu YQ, Cheng X, Zhou GB.

Cancer Sci. 2015 Apr 18. doi: 10.1111/cas.12679. [Epub ahead of print]


Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.

Haynes B, Saadat N, Myung B, Shekhar MP.

Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:258-66. doi: 10.1016/j.mrrev.2014.11.005. Epub 2014 Nov 20. Review.


Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.

Peremartí J, Ramos F, Marcos R, Hernández A.

Toxicol Sci. 2014 Nov;142(1):93-104. doi: 10.1093/toxsci/kfu159. Epub 2014 Aug 4.


FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.

Patil AA, Sayal P, Depondt ML, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M, Carroll TA, Collis SJ.

Oncotarget. 2014 Aug 15;5(15):6414-24.


The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.

Yao C, Du W, Chen H, Xiao S, Huang L, Chen F.

Leuk Lymphoma. 2015 Mar;56(3):755-62. doi: 10.3109/10428194.2014.935363. Epub 2014 Aug 18.


Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.

Jun DW, Hwang M, Kim HJ, Hwang SK, Kim S, Lee CH.

PLoS One. 2013 Oct 4;8(10):e75905. doi: 10.1371/journal.pone.0075905. eCollection 2013.


Discovery of novel drugs for promising targets.

Martell RE, Brooks DG, Wang Y, Wilcoxen K.

Clin Ther. 2013 Sep;35(9):1271-81. doi: 10.1016/j.clinthera.2013.08.005. Review.


Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Martínez S, Pérez L, Galmarini CM, Aracil M, Tercero JC, Gago F, Albella B, Bueren JA.

Br J Pharmacol. 2013 Oct;170(4):871-82. doi: 10.1111/bph.12331.


DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.

Shukla P, Solanki A, Ghosh K, Vundinti BR.

Eur J Haematol. 2013 Nov;91(5):381-93. doi: 10.1111/ejh.12169. Epub 2013 Aug 17. Review.


Fanconi anemia pathway--the way of DNA interstrand cross-link repair.

Yao CJ, Du W, Zhang Q, Zhang F, Zeng F, Chen FP.

Pharmazie. 2013 Jan;68(1):5-11. Review.


Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models.

Bakker ST, de Winter JP, te Riele H.

Dis Model Mech. 2013 Jan;6(1):40-7. doi: 10.1242/dmm.009795. Review.


Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.

Hedvat M, Emdad L, Das SK, Kim K, Dasgupta S, Thomas S, Hu B, Zhu S, Dash R, Quinn BA, Oyesanya RA, Kegelman TP, Sokhi UK, Sarkar S, Erdogan E, Menezes ME, Bhoopathi P, Wang XY, Pomper MG, Wei J, Wu B, Stebbins JL, Diaz PW, Reed JC, Pellecchia M, Sarkar D, Fisher PB.

Anticancer Agents Med Chem. 2012 Nov;12(9):1143-55. Review.


Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

Jenkins C, Kan J, Hoatlin ME.

Anemia. 2012;2012:481583. doi: 10.1155/2012/481583. Epub 2012 May 24.


Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.

Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T.

Mol Cancer. 2012 Apr 26;11:26. doi: 10.1186/1476-4598-11-26.


Ethnopharmacokinetic- and activity-guided isolation of a new antidepressive compound from fructus aurantii found in the traditional chinese medicine chaihu-shugan-san: a new approach and its application.

Fan R, Huang X, Wang Y, Chen X, Ren P, Ji H, Xie Y, Zhang Y, Huang W, Qiu X, Liu Z, Zhou H, Fan L, Gao L.

Evid Based Complement Alternat Med. 2012;2012:607584. doi: 10.1155/2012/607584. Epub 2012 Feb 1.


Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.

Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, D'Andrea AD.

Mol Cancer Res. 2012 Mar;10(3):369-77. doi: 10.1158/1541-7786.MCR-11-0497. Epub 2012 Jan 4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk